What happens to your current medications when you enter residential treatment: how medication reconciliation works, why benzodiazepines, opioids and stimulants get a closer look, and a checklist to complete before you call admissions.
Thinking about leaving residential treatment early? Here is what an AMA discharge involves, why the first 24 hours carry medical risk, and five things to ask staff for before you walk out.
Can you smoke or vape in residential treatment? How programs handle nicotine, the seven FDA-approved quit medications, how nicotine withdrawal overlaps with other withdrawal, and the questions to ask admissions before you arrive.
How buprenorphine is started in residential treatment: what the 11-item, 0-to-48 COWS score measures, why fentanyl changed induction, and five questions to ask admissions before the intake date.
Residential stays commonly run 30 to 90 days, and insured stays are usually reauthorized every 7 to 14 days. Here is how length of stay is decided and what to ask admissions before day one.
There is no FDA-approved medication for methamphetamine or cocaine use disorder. Here is how that changes residential treatment planning, length of stay and discharge, plus five questions to ask admissions.
How the 10-item CIWA-Ar scale tracks alcohol withdrawal during medically supervised detox, the 6 to 96 hour timeline it watches, and the six facts to write down before calling residential admissions.
Most California sober living homes are not licensed by DHCS. Here is how the four NARR support levels work, what we see in placement work, and seven questions to ask before move-in.
Leaving residential treatment with naloxone is a discharge-planning item, not an afterthought. How to get it in California, where to store it, the 2-to-3-minute two-dose instruction, and the 10-minute household check to run your first night home.
A benzodiazepine taper is usually measured in weeks to months, not days. How taper pace is set under the 2025 ASAM-led guideline, why it often continues after residential discharge, and five things to confirm before admission.
Cannabis Use Disorder and Residential Treatment: The Two-Week Withdrawal Window, Hyperemesis, and What to Tell AdmissionsOctober 23, 2026 - 9:39 pm
Young Adults on a Parent’s Insurance and Residential Treatment: The Age-26 Rule, the Age-18 Privacy Line, and What to Tell AdmissionsOctober 23, 2026 - 3:02 pm
Ketamine Use and Residential Treatment: No Detox Medication, Bladder Symptoms, Prescribed Ketamine, and What to Tell AdmissionsOctober 22, 2026 - 3:03 pm
Meth and Cocaine Use Disorder in Residential Treatment: The 2-of-11 Rule, No FDA-Approved Medication, and What to Tell AdmissionsOctober 21, 2026 - 8:52 pm
Click to Call